Cardiol Therapeutics (CT9) Stock Statistics & Valuation Metrics
Total Valuation
Cardiol Therapeutics has a market cap or net worth of EUR 108.09M. The enterprise value is EUR 145.28M.
- Market Cap
- EUR 108.09M
- Enterprise Value
- EUR 145.28M
Share Statistics
Cardiol Therapeutics has 120,660,446 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 120,660,446
- Owned by Insiders
- 1.13%
- Owned by Institutions
- 0.65%
Financial Efficiency
Cardiol Therapeutics’s return on equity (ROE) is -1.89 and return on invested capital (ROIC) is -190.61%.
- Return on Equity (ROE)
- -1.89
- Return on Assets (ROA)
- -1.43
- Return on Invested Capital (ROIC)
- -190.61%
- Return on Capital Employed (ROCE)
- -1.91
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.88M
- Employee Count
- 18
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Cardiol Therapeutics is -4.10. Cardiol Therapeutics’s PEG ratio is -0.11.
- PE Ratio
- -4.10
- PS Ratio
- 0.00
- PB Ratio
- 6.74
- Price to FCF
- -7.06
- Price to Operating Cash Flow
- -6.74
- PEG Ratio
- -0.11
Income Statement
In the last 12 months, Cardiol Therapeutics had revenue of 0 and earned -33.82M in profits. Earnings per share was -0.39.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -34.32M
- Pretax Income
- -33.82M
- Net Income
- -33.82M
- EBITDA
- -34.21M
- Earnings Per Share (EPS)
- -0.39
Cash Flow
In the last 12 months, operating cash flow was -24.05M and capital expenditures -56,726, giving a free cash flow of -24.10M billion.
- Operating Cash Flow
- -24.05M
- Free Cash Flow
- -24.10M
- Free Cash Flow per Share
- -0.21
Dividends & Yields
Cardiol Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.17%
- Earnings Yield
- -21.03%
Stock Price Statistics
- Beta
- 0.69
- 52-Week Price Change
- -1.52%
- 50-Day Moving Average
- 1.33
- 200-Day Moving Average
- 1.09
- Relative Strength Index (RSI)
- 33.95
- Average Volume (3m)
- 4,304
Important Dates
Cardiol Therapeutics upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Cardiol Therapeutics as a current ratio of 4.16, with Debt / Equity ratio of 0.70%
- Current Ratio
- 4.16
- Quick Ratio
- 4.16
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.62
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Cardiol Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Cardiol Therapeutics EV to EBITDA ratio is -4.06, with an EV/FCF ratio of -5.98.
- EV to Sales
- 0.00
- EV to EBITDA
- -4.06
- EV to Free Cash Flow
- -5.98
- EV to Operating Cash Flow
- -5.99
Balance Sheet
Cardiol Therapeutics has EUR 26.08M in cash and marketable securities with EUR 107.00K in debt, giving a net cash position of EUR 25.97M billion.
- Cash & Marketable Securities
- EUR 26.08M
- Total Debt
- EUR 107.00K
- Net Cash
- EUR 25.97M
- Net Cash Per Share
- EUR 0.22
- Tangible Book Value Per Share
- EUR 0.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Cardiol Therapeutics is EUR 8.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 8.92
- Price Target Upside
- 961.96% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 33.62%
Scores
- Smart Score
- 6
- AI Score
- ―
